-
Atlantic Health targets polypharmacy
Morristown, N.J.-based Atlantic Health System will soon deploy an AI-based technology that flags polypharmacy issues, or problems related to taking five or more medications. -
The nation's 15 biggest pharmacies
With $159.4 billion, CVS Health accounts for a fourth of the U.S. pharmacy industry, according to 2023 prescription dispensing revenue data compiled by Drug Channels. -
10 of 20 most popular drugs are in shortage
In the first quarter of 2024, the U.S. hit a 23-year record after logging 323 active drug shortages. And among GoodRx's list of the nation's 20 most popular therapies, half are in shortage. -
Top 15 specialty pharmacies by 2023 revenue
Two in five accredited specialty pharmacies are owned by hospitals and other healthcare providers, but the nation's three biggest pharmacy benefit managers accounted for 67% of specialty pharmacy revenue in 2023, according to Drug Channels. -
Leqembi's rollout becomes a crawl
About nine months after the FDA fully approved an Alzheimer's drug for the first time, the medicine is trudging through insurance barriers and hesitations from potential patients, the Chicago Tribune reported April 12. -
Pfizer to lay off 119, wind down plant's construction
Pfizer plans to lay off 119 workers at a facility in Everett, Wash., which the drugmaker acquired in its Seagen deal. -
Congress probes popular China-based drugmaker
WuXi AppTec, a drugmaker in China that manufactures multiple chemotherapies for U.S. patients, is facing scrutiny from lawmakers concerned about security threats, The New York Times reported April 15. -
The state of hospital pharmacies in 2024: 10 notes
In 2024, healthcare pharmacy executives are focused on standardizing their formularies and streamlining drug purchasing, according to 275 hospital pharmacy leaders surveyed by Bluesight. -
California drugmaker weighs sale
Janux Therapeutics, a biopharmaceutical company based in San Diego, is considering selling the business and other options, people with knowledge of the matter told Bloomberg. -
Drug shortages hit 23-year high: ASHP
The number of ongoing drug shortages in the U.S. is at its highest since 2001 — when the American Society of Health-System Pharmacists began tracking data. There are now 323 medications in low supply. -
RSV vaccine is safe for young, middle-aged adults: Pfizer
The U.S. might soon see an approved respiratory syncytial virus vaccine for adults younger than 60. -
The pros and cons of MA's biosimilar rule, per 1 pharmacist group
Biosimilars can now be substituted as part of regular formulary maintenance changes, according to CMS' Medicare Advantage and Part D Final Rule for 2025. However, the change could significantly increase patient cost sharing, according to an article on the American Society of Health-System Pharmacists website. -
Top PBMs by 2023 market share
Three pharmacy benefit managers accounted for nearly 80% of all prescription claims handled in 2023, according to an April 9 report from the Drug Channels Institute. -
How pharmacy miscommunication can result in patient death: Case study
A jury awarded $42.4 million to the estate of a patient who died after staff failed to get the patient's baclofen prescription filled in a timely manner, a case study posted on the American Pharmacy Association website said. -
25 drugs at Mark Cuban's online pharmacy with biggest cost reductions
Customers of Mark Cuban Cost Plus Drug Co.'s mail-order pharmacy can now save more than $20,000 on the cancer drug everolimus. -
Kaiser pharmacists secure mid-contract wage increases
UFCW 3000, a union representing about 50,000 workers at health systems, retail stores and other businesses in three states, said it secured wage increases for some Kaiser Permanente employees. -
New York drugmaker files for bankruptcy
Acorda Therapeutics filed for Chapter 11 bankruptcy April 1. -
Pharmacist pay by state
The average pharmacist's salary in the U.S. is $134,790, and 15 states and Washington, D.C., are above the average, according to the most recent data from the Bureau of Labor Statistics. -
HHS 'misses the mark' in drug shortage proposal, ASHP says
The American Society of Health-System Pharmacists partly welcomed HHS' 18-page policy recommendations for drug shortage strategies, but the organization said it "proposes concerning penalties." -
Amylyx to swipe ALS from market after study failure
Amylyx Pharmaceuticals is withdrawing its FDA-approved therapy for amyotrophic lateral sclerosis, Relyvrio, from the market after a phase 3 study failure, the company said April 4.
Page 22 of 50